Search for a clinical trial
Other search option(s)
29 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Study involving ERN members in at least two Member States = 
National clinical trial(s)
AUSTRIA
WIEN
WIEN
PACE ACE: Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study (Phase 2)
Universitätsklinikum - AKH Wien
Klinische Abteilung für Onkologie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
FRANCE
AUVERGNE-RHONE-ALPES
LYON
A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (Phase II) - BE
CLCC Léon Bérard
Cancérologie médicale - Gynécologie médicale, Tumeurs rares de l'ovaire
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
RAINBOW : A randomized, multicenter, double-blind, placebo-controlled phase 3 study of weekly paclitaxel with or without ramucirumab (IMC-1121B) drug product in patients with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine - FR
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) - FR
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
LILLE
ANGIO-TAX-PLUS - Etude de phase II multicentrique, randomisée et stratifiée comparant l'efficacité du Paclitaxel hebdomadaire seul ou en association au Bevacizumab dans le traitement des angiosarcomes métastatiques ou localement avancés non accessibles à un traitement chirurgical.
CLCC Oscar Lambret
Département de cancérologie générale
FRANCE
NORMANDIE
CAEN
TAPAZ : A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Centre François Baclesse
CLCC François Baclesse
GERMANY
Baden-Württemberg
HEIDELBERG
CUPISCO: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy -DE
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
GERMANY
Baden-Württemberg
MANNHEIM
EVA Study: Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA) - DE
Universitätsmedizin Mannheim
Sarkom-Zentrum
GERMANY
Baden-Württemberg
TÜBINGEN
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma - DE -completed-
Zentrum für Dermatoonkologie am Universitätsklinikum Tübingen
Sektion Dermatologische Onkologie
GERMANY
Bayern
MÜNCHEN
RAMOS study: A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für Innere Medizin III: Hämatologie und Onkologie
GERMANY
Berlin
BERLIN
HECTOR: A randomised, multicenter phase III study: Topotecan plus Carboplatine in comparison to the standard regimes (Paclitaxel plus Carboplatine or Gemcitabine plus Carboplatine) in patients with platin sensitive relapsed ovarian epithelial carcinoma, peritoneal carcinoma or carcinoma of fallopian tube - DE
Charité - Universitätsmedizin Berlin (CVK)
Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK)
GERMANY
Hessen
FRANKFURT AM MAIN
RAMOS study: A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs
Krankenhaus Nordwest GmbH
Institut für Klinische Krebsforschung IKF GmbH
GERMANY
Nordrhein-Westfalen
BIELEFELD
Phase II trial of Pemetrexed combined with Paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic Thyroid Cancer (PANTHERA) - DE
Franziskus Hospital Bielefeld
Klinik für Hämatologie, Onkologie und Immunologie
GERMANY
Nordrhein-Westfalen
ESSEN
ALIENOR (GINECO-OV222): A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours - DE
Evang. Kliniken Essen-Mitte gGmbH
Klinik für Gynäkologie & Gynäkologischer Onkologie
GERMANY
Nordrhein-Westfalen
ESSEN
BOUQUET: A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors -DE
Evang. Kliniken Essen-Mitte gGmbH
Klinik für Gynäkologie & Gynäkologischer Onkologie
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) - IT
Institution: Information not provided - IT
ITALY
EMILIA ROMAGNA
BOLOGNA
Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma
IRCCS Azienda Ospedaliero Universitaria di Bologna, Policlinico di Sant'Orsola
S.S.D. Oncologia Medica
ITALY
LAZIO
ROMA
The NUVOLA TRIAL: Neoadjuvant Chemotherapy in Unresectable oVarian Cancer With OLAparib and Weekly Carboplatin Plus Paclitaxel: A Phase II Open-label Multicentre Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Ginecologia Oncologica
SLOVAKIA
Bratislavsky kraj
BRATISLAVA
First Line TIP in Poor Prognosis TGCTs. (TIP)
National Cancer Institute
Department of cancer genetics
SPAIN
Castilla - León
SALAMANCA
Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer - ES (Completed)
Complejo Asistencial Universitario de Salamanca
Servicio de Oncología Médica
SPAIN
Cataluña
BARCELONA
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma - ES (completed)
Hospital Clínic de Barcelona
Unidad de melanoma familiar
SPAIN
Cataluña
BARCELONA
Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck [...] - ES (completed)
Vall d'Hebron Instituto de Oncología - Centro Cellex
Vall d'Hebron Instituto de Oncología
SPAIN
Cataluña
SABADELL
NOVA: A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer - ES (completed)
Parc Taulí Hospital Universitari. Hospital de Sabadell
Servicio de Oncología
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
RAINBOW: A randomized, multicenter, double-blind, placebo-controlled phase 3 study of weekly paclitaxel with or without ramucirumab (IMC-1121B) drug product in patients with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine - ES (Completed)
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
TRINOVA-3: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers - ES (Completed)
Hospital Universitario La Paz
Servicio de Oncología Médica
SPAIN
Navarra
PAMPLONA
Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer - ES (Completed)
Hospital Universitario de Navarra
Servicio de Oncología médica
UNITED KINGDOM
Greater London
LONDON
A randomised placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer - SaPPrOC
St Bartholomew's Hospital, Barts and The London NHS Trust
Department of Medical Oncology
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK